|
【结 构 式】 
|
【药物名称】MnTDE-2-ImP5+, AEOL-10150 【化学名称】(SP-4-1)-[[2,2',2'',2'''-(21H,23H-Porphine-5,10,15,20-tetrayl-.kappaN21,.kappaN22,.kappaN23,.kappaN24)tetrakis[1,3-diethyl-1H-imidazoliumato]](2-)manganese(5+) pentachloride 【CA登记号】286475-30-7 【 分 子 式 】C48H56Cl5MnN12 【 分 子 量 】1033.26492 |
【开发单位】Incara (Orphan Drug), National Jewish Center (Originator), Incara (Licensee) 【药理作用】Amyotrophic Lateral Sclerosis, Agents for, Cerebrovascular Diseases, Treatment of, Ischemic Stroke, Treatment of, Neurodegenerative Diseases, Treatment of, NEUROLOGIC DRUGS, ONCOLYTIC DRUGS, Radioprotectants, Stroke, Treatment of, Antioxidants |
合成路线1
The tetraimidazolyl porphyrin (III) was prepared by reaction between 1-ethylimidazole-2-carboxaldehyde (I) and pyrrole (II) in refluxing propionic acid. Quaternization of the imidazole groups of (III) with iodoethane furnished the tetrakis-imidazolium iodide salt (IV). After complexation of porphyrin (IV) with manganese(III) acetate, its precipitation as the hexafluorophosphate salt followed by anion exchange with tetrabutylammonium chloride, furnished the title chelate pentachloride salt.
| 【1】 Trova, M.P.; Kitchen, D.B.; Crapo, J.D.; Gauuan, P.J.F.; Day, B.J. (National Jewish Medical and Research Center); Substd. porphyrins. EP 1155019; JP 2002535332; WO 0043395 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 58657 | 1-ethyl-1H-imidazole-2-carbaldehyde | C6H8N2O | 详情 | 详情 | |
| (II) | 21674 | 1H-pyrrole | 109-97-7 | C4H5N | 详情 | 详情 |
| (III) | 58658 | 2,7,12,17-tetrakis(1-ethyl-1H-imidazol-2-yl)-21,22,23,24-tetraazapentacyclo[16.2.1.1~3,6~.1~8,11~.1~13,16~]tetracosa-1,3,5,7,9,11(23),12,14,16,18(21),19-undecaene | C40H38N12 | 详情 | 详情 | |
| (IV) | 58659 | 1,3-diethyl-2-[7,12,17-tris(1,3-diethyl-1H-imidazol-3-ium-2-yl)-21,22,23,24-tetraazapentacyclo[16.2.1.1~3,6~.1~8,11~.1~13,16~]tetracosa-1,3,5,7,9,11(23),12,14,16,18(21),19-undecaen-2-yl]-1H-imidazol-3-ium tetraiodide | C48H58I4N12 | 详情 | 详情 |